Romidepsin Injection, Solution, Concentrate
Product Images NDC 70121-2250

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Romidepsin (NDC 70121-2250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Romidepsin Injection 1)

FDA Label Image

Label (Romidepsin Injection 2)

This is a medication information for Romidepsin Injection, intended for intravenous infusion. Each vial contains romidepsin, sorbitol, DL-alpha tocopherol, glycerol, and polyoxyethylene 20. It is a cytotoxic agent and should be diluted in 500 mL of 9% Sodium Chloride solution prior to use. The recommended dosage is specified, along with storage instructions between 20°C to 25°C. The product label includes important details such as the manufacturer, storage conditions, and lot number for identification and tracking purposes.*

FDA Label Image

Carton (Romidepsin Injection 3)

This is a label containing detailed information about Romidepsin Injection, a cytotoxic agent for intravenous infusion. The product is manufactured by Amneal Oncology Pvt Ltd. in India and distributed by Amneal Pharmaceuticals LLG in the US. Each mL contains romidepsin, povidone, DL-alpha-tocopherol, dehydrated alcohol, and propylene glycol. The recommended dosage and storage instructions are provided, along with a caution to keep the product out of reach of children. The label specifies that the product must be diluted before use and to discard any unused portion. For more information, a contact number is provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.